Eli Lilly's FDA Approval: A Catalyst for Market Momentum
Eli Lilly's recent FDA approval sparks momentum in LLY's stock and the broader market, with the Dow rising significantly.
Curium and Lantheus Merger: A Game-Changer for Radiopharmaceuticals
Curium and Lantheus' $8 billion merger could reshape the radiopharmaceutical landscape and offer significant benefits to shareholders.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Integer Holdings to Go Private: Analyzing the KKR Acquisition
Integer Holdings is set to be acquired by KKR for $5.7 billion, raising questions about the future of the medical device…
Supernus and Indivior Merger: A New Era for CNS Biopharmaceuticals
Supernus and Indivior's all-stock merger could reshape the CNS biopharmaceutical landscape significantly.
Curium's $8 Billion Acquisition of Lantheus: What it Means for Investors
Curium's $8 billion acquisition of Lantheus could reshape the radiopharmaceutical landscape. Here's what investors need …
Replimune's RP1 Approval Decision: A High-Stakes Moment for Biotech Investors
The FDA's impending decision on Replimune's RP1 could reshape the biotech landscape, especially for shareholders amid pa…
KKR Eyes Integer Holdings: A Potential Game-Changer for Medical Device Sector
KKR's potential acquisition of Integer Holdings at $127 per share has significant implications for the medical device se…
Novo Nordisk Faces Setback as Cardiovascular Drug Trial Fails
Novo Nordisk's ziltivekimab trial failure sends NVO shares tumbling, raising concerns about the company's future in the …
KKR's Potential Acquisition of Integer Holdings: Market Implications and Investor Insights
Integer Holdings (ITGR) gains on KKR's $127 per share acquisition talks, signaling trends in healthcare investing.
Novo Nordisk's Ziltivekimab Trial Failure: A Critical Moment for Investors
Novo Nordisk (NVO) shares dropped 9-10% after ziltivekimab missed key trial goals, raising concerns about its pipeline a…
Replimune's FDA Panel Victory: What Investors Need to Know About RP1 and Its Market Impact
Replimune's shares surged 127-133% following FDA panel support for RP1. Explore the implications for investors and marke…